Found: 5
Select item for more details and to access through your institution.
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 19, p. 3278, doi. 10.1002/cncr.35387
- By:
- Publication type:
- Article
Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending.
- Published in:
- Oncologist, 2020, v. 25, n. 2, p. e391, doi. 10.1634/theoncologist.2019-0467
- By:
- Publication type:
- Article
A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review.
- Published in:
- Frontiers in Medicine, 2024, p. 1, doi. 10.3389/fmed.2024.1402902
- By:
- Publication type:
- Article
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
- Published in:
- Science Translational Medicine, 2024, v. 16, n. 731, p. 1, doi. 10.1126/scitranslmed.add1834
- By:
- Publication type:
- Article
Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 8, p. 1335, doi. 10.1002/ijc.34126
- By:
- Publication type:
- Article